Although neither group reached mOS, the T-DXd group showed a significant trend toward prolongation and a significantly reduced mortality risk (hazard ratio (HR) = 0.64, p = 0.0037).
← all excerpts
Clinical application and optimization strategies for antibody-drug conjugates in solid tumors.
1
—
—